Introduction
Prostate cancer is the most commonly diagnosed male cancer in Scandinavia and most other western countries, where 10,452 incident cases were diagnosed in Sweden 2014 [1] . Although the introduction of PSA as a diagnostic tool at the end of the last century has led to a marked stage migration of the disease with an increasing proportion of prostate cancer cases being diagnosed at a clinically localised stage, many men still have distant metastases at diagnosis (12% in Sweden in 2014) [1] . Once the tumour has metastasised the disease is practically incurable, albeit many men live for several years with generalised prostate cancer [2, 3] .
Because of variations in clinical background, survival following standard androgen deprivation treatment (ADT) varies greatly [4] . Metastases most frequently (>90%) involve the bone, and the extent of these metastases at diagnosis has a great influence on the patient's fate [5] .
Traditionally, radionuclide imaging of the skeleton with measurement of bone uptake is used to diagnose metastatic bone involvement [6] . Soloway and co-workers proposed a graded classification of extent of bone metastasis, estimating the number and size of bone metastases prior to treatment [7] . By quantifying the extent of metastasis to the bone, a better prediction of survival was achieved than when relying on M1b-categorisation alone.
Recent clinical trials tested a new concept of systemic therapy for hormone-naïve metastatic prostate cancer and it was shown that chemo-hormonal therapy, i.e. six cycles of docetaxel at the beginning of ADT, resulted in significantly longer overall survival than ADT alone [8] [9] [10] .The clinical benefit was particularly pronounced among patients with high-volume disease.
In this context it is important to identify which patients are likely to benefit from a new treatment modality, and to accurately distinguish these from the rest.
At present it is not fully clear how great the impact of bone metastasis at diagnosis is on pain, fatigue, deteriorated performance status and other clinical variables.
The aim of this study was to investigate the prognostic significance of the extent of bone metastasis in relation to other pre-treatment variables, and to explore the impact of bone metastasis on quality-of-life.
Material and methods
The SPCG 5 Trial. The cohort of 900 men in this study was derived from a prospective phase III non-inferiority clinical trial (No 5) conducted by the Scandinavian Prostate Cancer Group (SPCG). Primarily, 915 patients with hormone-naïve metastatic prostate cancer from 61 centres in Denmark, Finland, Iceland, Norway and Sweden between December 1992 and June 1997 were included [11, 12] . To be eligible, patients were required to have bone metastases (M1b) and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
The primary objective of the SPCG trial was to determine whether or not survival with high dose parenteral oestrogen therapy was inferior to that with TAB.
Serum concentrations of PSA and total alkaline phosphatase (ALP), and haemoglobin levels were determined by routine laboratory testing before the start of treatment.
Bone scanning and categorisation. The bone uptake of 99m technetium MPD was assessed in all patients according to local standard algorithms at each participating centre. Bone scans with multiple disseminated areas of increased activity were considered diagnostic of multiple metastases.
The extent of metastasis determined on bone scan was quantified according to a modified Soloway score (mSS) with three categories according to the extent of metastasis: Score 1 = the total area of hot spots less than three bodies of a lumbar vertebra; Score 2 = the total area of hot spots larger than Score 1, but <75% of the total scan; and Score 3 ≥75% of the total scan or super scan [7] . In 15 cases the extent of bone metastasis was not recorded, leaving 900 patients eligible for inclusion in this study.
Quality-of-Life. The European Organisation for Research and Treatment of Cancer Qualityof-Life Questionnaire-C30 version 1 (EORTC-30) was used to evaluate quality-of-life (QoL) [13] . The questionnaire was designed to be cancer-specific and has been utilised in several international clinical trials. It is available in Danish, Swedish, Norwegian and Finnish translations. The questionnaire is appropriate for self-administrations and consists of 30 items, including nine multi-item scales, five functional scales, three symptom scaled and a global health status scale and single items, adding up to a total of 15 ratings. The raw scores from the questionnaire were linearly transformed into a standardised 0-100 scale score.
Follow-up. The men included were scheduled for follow-up one, three and six months after start of the study and thereafter every six months. Time to death was determined from the date of treatment initiation.
Ethics.
The study was performed in accordance with the recommendations of the Helsinki Declaration and approved by the ethics committees of all centres partaking in the study.
Patients were given verbal and written information, and gave their informed consent to be included in the study.
Statistical methods.
In the study cohort of 900 men, the extent of bone metastasis was graded according to the mSS. Clinical characteristics were sorted according to mSS. The mean values of EORTC-30 ratings at baseline related to extent of bone metastasis were tested by analysis of variance (ANOVA). The primary outcome was overall survival. Survival was defined as the interval between the date of inclusion and the date of death or end of follow-up, whichever came first. Two patients in the mSS 1 group had no valid follow-up information. Cumulative overall survival related to extent of bone metastasis was assessed using Kaplan-Meier curve analysis. A univariate Cox regression model was then used to assess the risk for death according to the mSS. In a next step, the mSS and each clinical characteristic were included in a stepwise Cox regression model (treatment, age, cancer-related pain, ECOG performance status, analgesic consumption, grade of malignancy, T-category, cardiovascular comorbidity, ALP, PSA, haemoglobin, testosterone, quality of life). The clinical variables that had a confounding impact on the estimation of mSS were included in the final multivariate regression model. In order to identify independent predictors within the mSS groups, multivariate Cox regression models were constructed using all variables that were statistically significant in the univariate analyses, stratifying for mSS. In the sensitivity analyses, mSS 2 and 3 were aggregated into one group and the univariate and the multivariate analyses were repeated. In a subsequent step, we repeated all the survival analyses considering cancerspecific mortality only. All p-values were two-sided and statistical significance was considered at p <0.05. All analyses were performed using the R version 3.1.1.
Results
Baseline characteristics for the 900 patients enrolled in the study cohort are presented in table 1 as groups according to the extent of bone metastasis (Soloway score). Most men had Score 2 at inclusion (53.7%). The median follow-up was 75.6 months (39.2-139.3 months), during which 841 men died. Median follow-up was shorter with a higher mSS. Cancer-related pain, analgesic consumption, T-category, ALP, PSA, and haemoglobin were all differed significantly between the mSS groups ( Table 1) .
The mean global health status decreased from 64.4 to 50.5 at mSS 1 and 3, respectively ( Table 2 ). Four of five functioning scales showed decreased rating with increased mSS; mean physical functioning was 81.4 for Score 1 and 65.7 for Score 3 (p<0.001). Most symptoms, including fatigue, pain, and insomnia were significantly more pronounced in patients with a higher mSS ( Table 2 ).
Overall survival was higher among patients with mSS 1 at inclusion (5-year 39% 95% CI 34-45%) compared to those with Scores 2 (5-year 17%, 95% CI 14-21%) and 3 (5-year 9%, 95% CI 5-17%), respectively. This was also confirmed in a univariate Cox Regression model Independent prognostic factors associated with overall mortality risk according to extent of metastasis were defined using multivariate Cox regression analysis (Table 3) . Poor performance status, high analgesic consumption, high grade of malignancy and high level of PSA were all independent risk factors for mortality in patients with mSS 1. On the contrary, a high haemoglobin and good global health status were both associated with lower mortality in patients with mSS 1. In patients with mSS 2, poor performance status, high grade of malignancy and elevated ALP were independent risk factors, while a high haemoglobin and good global health status were independent factors for lower mortality (Table 3 ). In the mSS 3 group, only the level of haemoglobin had a significant impact on mortality (Table 3 ).
In the sensitivity analyses, performance status, ALP, haemoglobin, and global health status were all independent prognostic factors of overall mortality when Score Groups 2 and 3 were taken together. In an analysis limited to cancer-specific mortality, grade of malignancy and PSA level were independent predictive factors for mSS 1. Base-line demographic and disease characteristics were similar between treatment groups. No significant differences in overall or disease specific survival were observed and thus, treatment was not included in the multivariate models. Data on quality of life prior to start of endocrine treatment and during treatment were obtained from all patients but not analysed according to the different forms of treatment [14] . Performance status, grade of malignancy, ALP, and global health status were independent predictive factors for mSS 2 group, whereas in the Score 3 group haemoglobin level was the only predictive factor.
Discussion
This study confirms the importance of quantitative assessment of the extent of bone metastasis in men with M1b prostate cancer. The extent of bone disease, according to the mSS, had a crucial impact on expected quality-of-life and survival. The subgroups of men with widespread metastasis but without performance status deterioration are probably those that benefit the most from combined endocrine treatment with chemotherapy.
Although all men in the present study had bone metastases, they had reached different levels in the metastatic process at diagnosis. In the present study a mSS was constructed with three score categories based on visual estimation of the total area of lesions on bone scan images.
Originally, Soloway and co-workers graded the extent of the disease into four categories.
Their original grading system showed significant associations with survival for Scores 1 and 4, but Scores 2 and 3 did not differ significantly [7] . Therefore, the original Soloway Scores 2 and 3 included as Score 2 in the modified Solowey Score of the SPCG 5 trial.
Using recursive partitioning of several variables Glass et al. developed three prognostic groups that were significantly predictive of overall survival [15] . Their 5-year overall survival was very similar to our estimates for Score Groups 1, 2 and 3: 42%, 21% and 9% respectively.
The validity and clinical relevance of the criteria for the prognostic grouping of Glass and coworkers were corroborated by a significant difference in overall survival between the good and intermediate and the good and poor prognostic groups. However, the difference between the intermediate and poor prognostic groups was not statistically significant [16] .
A number of large randomised clinical trials of ADT in hormone-naïve metastatic prostate cancer, summarised in table 4, have reported the extent of bone metastasis to be an important mortality risk factor. In the crude time to event analysis we included all the baseline characteristics within each group of mSS (Table 1) . In a next step we only included the baseline characteristics that had statistically significant impact on mortality in the crude analysis into the multivariate models.
When reviewing independent prognostic factors at diagnosis for patients with M1 disease, performance status, extent of bone metastasis, Gleason score, and ALP level are the most important measures previously identified. Other variables, such as age at diagnosis, pain, analgesic consumption, T-category, haemoglobin, PSA level, and testosterone levels are less frequently stated in the literature as being significant prognostic factors [17] .
Data with respect to QoL in patients with untreated metastatic prostate cancer are limited [18] .
Most attention has been paid to the QoL in prostate cancer patients with localised disease [19] . Our study shows significantly poorer QoL with increasing extent of metastasis. These results are in accordance with Rosenfeld et al concluding that higher cancer stage appears to be associated with poorer QoL in prostate cancer [20] .
ALP is widely used as a marker of skeletal involvement in prostate cancer. Elevated ALP was significantly related to worse survival in univariate analyses [16] . Prognostic factors from the GETUG-15 trial were used to define three prognostic subgroups of survival in hormone-naïve prostate cancer. ALP alone accounted for all the differences in survival regardless of degree of metastasis. One should be wary of drawing any conclusion from this; ADT could have been initiated up to two months before inclusion into the study, so that flare, a transient increase in ALP following ADT, could itself have increased ALP values [21] . In our multivariate analyses elevated ALP (>1.25 times upper limit of normal) was an independent prognostic factor for poor survival in the mSS 2 group, and even Score Groups 2 and 3 together.
In our study PSA level (> 233 µg/l) was an independent prognostic factor for adverse outcome in patients with mSS 1, but not in those with Scores 2 or 3. In the three prognostic groups based on the SWOG 8894 trial, a PSA level >65 µg/l had a major negative impact on survival, but a lower PSA level before start of treatment suggests that those patients were diagnosed at an earlier stage in the metastatic process than were the patients in our study [15] .
A low haemoglobin was predictive of poor outcome in patients undergoing ADT in univariate [22] and multivariate [23] analyses. Low haemoglobin (<124 g/L) was the only statistically significant independent variable associated with poor survival in patients with all three mSS.
Anaemia may lead to therapy resistance either directly or by association. Hypoxia due to anaemia may contribute to treatment resistance. Several cytokines associated with anaemia may promote cancer metastases in the bone microenvironment and contribute to progress of bone metastases and mortality [24, 25] .
In clinical studies high T-category [22] or high Gleason score [15] correlated significantly with poor survival. Also autopsy, routinely performed on patients dying of prostate cancer showed a strong relationship between extent of metastasis, high T-category and Gleason score [5] .
Limitations. We did not have data on detailed numbers and locations of bone metastases and could therefore not say whether they were axial (pelvic bones and spine) or appendicular (long bones, skull), which has been a discriminating factor between risk groups in other trials [9, 10, 26] . At inclusion men with de novo metastatic disease and patients progressing from localised disease to metastases were not recorded separately. Most likely the population of the patients in this trial had a high proportion of men with de novo metastatic disease, which is not typical for men with prostate cancer diagnosed nowadays. Visceral and non-regional lymph node metastases were not evaluated at inclusion in this study. However, according to some studies, visceral metastasis (M1c) has a low prevalence; lung (2%-11%) and liver (0.4%-3%) [9, 10] . The adverse predictive value is not clear. No attempt has been made to classify or quantify metastases in other sites than bone.
Strength of the study. To our knowledge this study is the first to subdivide M1b disease into three groups, based on the extent of bone metastasis, in order to explore any significant difference in overall and disease-specific survival. Our prognostic model was based on a large data set from a relatively homogeneous patient population with follow-up over a long period with sufficient event rate. We routinely used clinically relevant measurable variables, including QoL.
In conclusion, M1b disease is a heterogeneous diagnosis and more accurately defined 
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